BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10944596)

  • 1. Capecitabine in the treatment of metastatic renal cell carcinoma.
    Oevermann K; Buer J; Hoffmann R; Franzke A; Schrader A; Patzelt T; Kirchner H; Atzpodien J
    Br J Cancer; 2000 Sep; 83(5):583-7. PubMed ID: 10944596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
    Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
    Amato RJ; Mohammad T
    J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
    Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
    Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
    Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
    Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
    Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.
    Jacobs A; Gold P; Weiden P; Aboulafia D; Rudolph R; Picozzi V; Thompson J
    Cancer Invest; 2000; 18(5):417-21. PubMed ID: 10834025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
    Stadler WM; Kuzel T; Dumas M; Vogelzang NJ
    J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
    Pagliaro LC; Perez CA; Tu SM; Daliani DD
    Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
    Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
    Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
    Atzpodien J; Hoffmann R; Franzke M; Stief C; Wandert T; Reitz M
    Cancer; 2002 Sep; 95(5):1045-50. PubMed ID: 12209689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.